Immuneering Corporation (IMRX)
Total Valuation
Immuneering has a market cap or net worth of $267.80 million. The enterprise value is $167.11 million.
Market Cap | 267.80M |
Enterprise Value | 167.11M |
Important Dates
The next earnings date is Tuesday, May 9, 2023, before market open.
Estimated Earnings Date | May 9, 2023 |
Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 26.44 million shares outstanding. The number of shares has increased by 93.84% in one year.
Shares Outstanding | 26.44M |
Shares Change (YoY) | +93.84% |
Shares Change (QoQ) | +0.05% |
Owned by Insiders (%) | 30.53% |
Owned by Institutions (%) | 44.81% |
Float | 13.92M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 844.92 |
Forward PS | 477.81 |
PB Ratio | 2.44 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 527.25 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.50, with a Debt / Equity ratio of 0.04.
Current Ratio | 13.50 |
Quick Ratio | 13.10 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -97.70%.
Return on Equity (ROE) | -39.70% |
Return on Assets (ROA) | -36.70% |
Return on Capital (ROIC) | -97.70% |
Revenue Per Employee | $4,283 |
Profits Per Employee | -$682,616 |
Employee Count | 74 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.77% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | +30.77% |
50-Day Moving Average | 5.48 |
200-Day Moving Average | 7.25 |
Average Volume (30 Days) | 43,618 |
Short Selling Information
The latest short interest is 863,461, so 3.27% of the outstanding shares have been sold short.
Short Interest | 863,461 |
Short Previous Month | 829,271 |
Short % of Shares Out | 3.27% |
Short % of Float | 6.20% |
Short Ratio (days to cover) | 21.86 |
Income Statement
In the last 12 months, Immuneering had revenue of $316,952 and -$50.51 million in losses. Loss per share was -$1.91.
Revenue | 316,952 |
Gross Profit | 158,830 |
Operating Income | -51.74M |
Pretax Income | -50.51M |
Net Income | -50.51M |
EBITDA | -49.72M |
EBIT | -50.51M |
Loss Per Share | -$1.91 |
Balance Sheet
The company has $105.52 million in cash and $4.84 million in debt, giving a net cash position of $100.68 million or $3.81 per share.
Cash & Cash Equivalents | 105.52M |
Total Debt | 4.84M |
Net Cash | 100.68M |
Net Cash Per Share | $3.81 |
Equity / Book Value | 109.85M |
Book Value Per Share | 4.16 |
Working Capital | 100.69M |
Cash Flow
In the last 12 months, operating cash flow was -$44.10 million and capital expenditures -$742,483, giving a free cash flow of -$44.84 million.
Operating Cash Flow | -44.10M |
Capital Expenditures | -742,483 |
Free Cash Flow | -44.84M |
FCF Per Share | -$1.70 |
Margins
Gross margin is 50.11%, with operating and profit margins of -16,325.77% and -15,937.29%.
Gross Margin | 50.11% |
Operating Margin | -16,325.77% |
Pretax Margin | -15,937.29% |
Profit Margin | -15,937.29% |
EBITDA Margin | -15,685.90% |
EBIT Margin | -15,937.29% |
FCF Margin | -14,148.44% |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -18.86% |
FCF Yield | -16.75% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | -93.84% |
Shareholder Yield | -93.84% |
Analyst Forecast
The average price target for Immuneering is $16.32, which is 61.11% higher than the current price. The consensus rating is "Buy".
Price Target | $16.32 |
Price Target Difference | 61.11% |
Analyst Consensus | Buy |
Analyst Count | 13 |
Revenue Growth Forecast (5Y) | 260.76% |
EPS Growth Forecast (5Y) | -20.23% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |